Immune Support
Research compounds studied for adaptive immunity modulation, antimicrobial defense, thymic function, and systemic inflammation reduction.
Most researched for Immune Support
Thymosin Alpha-1
The most clinically validated immune peptide in this category - used as an approved pharmaceutical in over 35 countries for hepatitis B, hepatitis C, and immunocompromised patients. Activates T-cell maturation and dendritic cell function to enhance adaptive immunity. The extensive clinical database and pharmaceutical track record make it the most evidence-based starting point in this category.
LL-37
aka Cathelicidin, Cathelicidin, CAMP, CAP-18
How it works: An antimicrobial host defense peptide that kills pathogens directly and recruits immune cells to sites of infection.
Antimicrobial (bacteria, fungi, viruses); immune modulation; wound healing
Research dose
0.1-1 mg, Variable; 1–3×/day or every other day
Real-world (reported)
Very limited community protocols — 0.25–0.5 mg SubQ daily or 3×/week.
Administration
SubQ / Topical
Timing
Any time
Cycle length
4–8 weeks
Real-world figures are community-reported, not medical advice.
Common side effects: Cytokine-like effects at high doses; injection-site reactions; headache
Community take: [ANECDOTAL] Very limited gray-market use. Niche antimicrobial/immune application. Most community experience from wound healing application.
- Onset
- Antimicrobial effects rapid; immune modulation 1–4 wks
- Half-life
- Hours
- Storage
- Dry: Fridge 2–8°C; freeze long-term; very light and heat sensitive · Reconstituted: Refrigerate; use within 14 days (less stable than most)
- Reconstitution
- Add 1 mL BAC water to 1 mg vial = 1 mg/mL
- Rare side effects
- Pro-inflammatory effects at high systemic doses; cytokine storm potential (theoretical)
- Contraindications
- Active autoimmune disease; pregnancy; cancer (angiogenic potential); Active psoriasis or psoriatic arthritis (LL-37 forms complexes with self-DNA/RNA; Systemic lupus erythematosus or NET-driven autoimmune conditions; Active rosacea (cathelicidin dysregulation is implicated in rosacea pathogenesis; Mast cell-mediated disorders or history of anaphylactoid reactions
- Drug interactions
- Immunosuppressants
- Recommended bloodwork
- CBC; CRP; cytokine panel if concerns
- Stacks well with
- KPV: gut healing combo. BPC-157: wound healing stack.
- Secondary uses
- Anti-inflammatory; anti-biofilm; potential anti-cancer
- Research status
- Preclinical extensive; some Phase 1/2 human trials; FDA PCAC review pending; limited gray-market protocols
- FDA status
- No
- Legal status
- US: Research use only; PCAC review pending · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $50–$150 / 1 mg vial
- Research evidence
- low
- Indications
- Antimicrobial peptide research; Innate immunity and host defense studies; Wound healing and tissue repair investigations; Anti-biofilm research
- Chemical data
- CAS 154947-66-7 · C205H340N60O53 · 4493.4 Da
- Amino acids
- 37 aa
Thymosin Alpha-1
aka Ta1, Thymalfasin, Zadaxin
How it works: Promotes T-cell maturation and dendritic cell activation to enhance the adaptive immune response.
Immune system enhancement; anti-viral; anti-tumor (adjunct); chronic fatigue; Long COVID
Research dose
1.6-3.2 mg, 2×/week
Real-world (reported)
1.6 mg SubQ 2×/week. Some run 4-week loading then 2×/month maintenance.
Administration
SubQ
Timing
Any time
Cycle length
2–6 months
Real-world figures are community-reported, not medical advice.
Common side effects: Mild injection-site reactions; rare flu-like symptoms (immune activation)
Community take: [ANECDOTAL] Well-respected in anti-aging and immune optimization community. 'Immune reset.' Used for Long COVID with community-reported benefit.
- Onset
- Immune parameter improvements 4–8 wks; clinical benefit months
- Half-life
- ~2h
- Storage
- Dry: Fridge 2–8°C; freeze long-term; protect from light · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 1 mL sterile water or BAC water to 1.6 mg vial = 1.6 mg/mL
- Rare side effects
- Rare autoimmune flare in predisposed individuals; hypersensitivity reactions
- Contraindications
- Active autoimmune disease requiring immunosuppression; organ transplant on immunosuppressants
- Drug interactions
- Immunosuppressants (antagonistic)
- Recommended bloodwork
- CD4/CD8 counts; NK cell activity (specialized labs); CBC; CRP
- Stacks well with
- Epitalon: anti-aging longevity stack. Thymalin: complementary thymic support.
- Secondary uses
- Hepatitis B and C (approved); HIV; sepsis; autoimmune modulation; longevity
- Research status
- Approved in 30+ countries (Zadaxin); Phase 3 trials for hepatitis; Long COVID trials ongoing; solid human safety data over 30+ years
- FDA status
- No
- Legal status
- US: Not FDA-approved; approved in 30+ countries; sold as research chemical in US · UK: Legal for research; Zadaxin available internationally via Rx · Canada: Legal to import for research · Australia: Schedule 4 (Rx) · EU: Approved in some EU countries (country-specific)
- Typical price
- $40–$80 / 1.6 mg vial
- Research evidence
- moderate
- Indications
- Chronic hepatitis B treatment; Immune reconstitution; Vaccine adjuvant research; Cancer immunotherapy adjunct
- Chemical data
- CAS 62304-98-7 · C129H215N33O55 · 3108.3 Da
- Amino acids
- 114 aa
Thymalin
aka Thymalin (thymus bioregulator extract), Thymic Factor, Thymalin Peptide
How it works: A thymus-derived peptide mixture that supports thymic function and immune system restoration with aging.
Immune senescence reversal; T-cell restoration; longevity
Research dose
5-10 mg, Daily ×10 day course
Real-world (reported)
5–10 mg SC daily ×10 consecutive days; 2 cycles/year. Part of Russian anti-aging 3-peptide stack.
Administration
SC / IM
Timing
Any time
Cycle length
10 days; 2× per year
Real-world figures are community-reported, not medical advice.
Common side effects: Generally well tolerated; mild injection-site reactions
Community take: [ANECDOTAL – Longevity community] Part of Russian anti-aging protocols. Used alongside Epitalon. Reports of improved immunity, energy, well-being during course.
- Onset
- Immune parameters 4–8 wks; subjective improvement during course
- Half-life
- Hours (peptide extract)
- Storage
- Dry: Fridge 2–8°C; freeze long-term · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 1 mL BAC water to 10 mg vial = 10 mg/mL; 5 mg dose = 50 IU
- Rare side effects
- Limited long-term human safety data outside Russian research
- Contraindications
- Autoimmune disease requiring immunosuppression; pregnancy; Known hypersensitivity to thymalin or bovine-derived biological products; Active autoimmune diseases in flare (thymalin may exacerbate autoimmune response; Organ transplant recipients on immunosuppressive therapy; Pregnancy and lactation (insufficient safety data)
- Drug interactions
- Immunosuppressants
- Recommended bloodwork
- CBC; CD4/CD8 ratio; NK cell activity
- Stacks well with
- Epitalon: telomere support. GHK-Cu: tissue repair. Thymosin Alpha-1: complementary immune support.
- Secondary uses
- Infection resistance; autoimmune modulation
- Research status
- Russian clinical research (Khavinson protocols); limited Western replication; animal lifespan studies positive
- FDA status
- No
- Legal status
- US: Research use only · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $30–$60 / 10 mg vial
- Research evidence
- low
- Indications
- Immune system restoration and modulation research; Aging and longevity studies; Thymic function and T-cell maturation research; Bioregulatory peptide therapy investigations
- Chemical data
- C16H19N3O5 · 333.34 Da
- Amino acids
- 50 aa
KPV
aka Lys-Pro-Val, alpha-MSH C-terminal tripeptide, KPV tripeptide
How it works: Blocks NF-kB inflammatory signaling pathways to reduce chronic inflammation.
GI inflammation; IBD/Crohn's; leaky gut; systemic anti-inflammatory
Research dose
250-1000 mcg, Once or twice daily
Real-world (reported)
500 mcg oral or SubQ daily for GI. SubQ for systemic anti-inflammatory.
Administration
SubQ / Oral
Timing
Any time
Cycle length
4–8 weeks
Real-world figures are community-reported, not medical advice.
Common side effects: Generally well tolerated; mild injection-site reactions
Community take: [ANECDOTAL] Growing use for IBD, leaky gut, Crohn's. Oral route popular for GI targeting. 'BPC-157 for the gut but with immune modulation added.'
- Onset
- GI effects within days; anti-inflammatory effects 1–2 wks
- Half-life
- Minutes
- Storage
- Dry: Fridge 2–8°C; freeze long-term · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 1 mL BAC water to 1 mg vial = 1 mg/mL; 500 mcg dose = 50 IU
- Rare side effects
- Limited long-term human safety data
- Contraindications
- Active malignancy (MC1R expressed in melanoma); pregnancy; Immunosuppressed states (theoretical - NF-kB inhibition may further compromise i; Pregnancy (no reproductive or developmental toxicity data available)Frequency di; Immunosuppressants (theoretical additive immunosuppression through overlapping N; NF-kB pathway drugs (theoretical pharmacodynamic interaction with agents targeti
- Drug interactions
- No significant documented interactions
- Recommended bloodwork
- GI symptom assessment (IBD activity scores); CRP; stool biomarkers (calprotectin)
- Stacks well with
- BPC-157: gut healing stack. LL-37: antimicrobial complement for gut infections.
- Secondary uses
- Wound healing; skin inflammation; immune modulation
- Research status
- Preclinical robust; some human cell studies; Phase 1/2 ongoing; FDA PCAC July 2026
- FDA status
- No
- Legal status
- US: Research use only; PCAC July 2026 · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $30–$60 / 1 mg vial
- Research evidence
- very-low
- Indications
- Inflammatory bowel disease research; Mucosal inflammation studies; Gut barrier function research; Anti-inflammatory peptide research
- Chemical data
- CAS 67727-97-3 · C16H30N4O4 · 342.4 Da
- Amino acids
- 11 aa
ARA-290
aka Cibinetide, Cibinetide, Innate Repair Receptor agonist, Helix B Surface Peptide
How it works: A targeted anti-inflammatory studied for repairing small nerve fibers and easing nerve pain, without the blood effects of related compounds.
Diabetic small fiber neuropathy; neuropathic pain; systemic anti-inflammatory
Research dose
4-8 mg, Once daily or 3×/week
Real-world (reported)
4 mg SubQ daily or 3×/week. Following Phase 2 trial dosing as guide.
Administration
SubQ
Timing
Any time
Cycle length
4–12 weeks
Real-world figures are community-reported, not medical advice.
Common side effects: Generally well tolerated; injection-site reactions; mild nausea (rare)
Community take: [ANECDOTAL] Used by community members with neuropathic pain, fibromyalgia, sarcoidosis. Reports of significant nerve pain reduction. Limited gray-market experience.
- Onset
- Neuropathic symptom improvement 4–8 wks
- Half-life
- Hours
- Storage
- Dry: Fridge 2–8°C; freeze long-term · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 2 mL BAC water to 8 mg vial = 4 mg/mL
- Rare side effects
- Limited long-term data outside Phase 2 trials
- Contraindications
- EPO-sensitive conditions (theoretical); pregnancy; Pregnancy and breastfeeding (no safety data); Known hypersensitivity to ARA-290 or any excipients; Active erythropoiesis-stimulating agent therapy (theoretical interaction)Frequen; Erythropoiesis-stimulating agents (potential receptor competition)
- Drug interactions
- No significant documented interactions
- Recommended bloodwork
- Nerve conduction studies; intraepidermal nerve fiber density; CRP; pain scores
- Stacks well with
- BPC-157: systemic healing stack. Thymosin Alpha-1: immune complement.
- Secondary uses
- Sarcoidosis (Phase 2); sepsis; organ protection
- Research status
- Phase 1/2 human trials for small fiber neuropathy and sarcoidosis; solid human safety data
- FDA status
- No
- Legal status
- US: Research use only (no FDA approval); Phase 2/3 pipeline · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $80–$200 / 8 mg vial
- Research evidence
- moderate
- Indications
- Small fiber neuropathy in sarcoidosis; Diabetic peripheral neuropathy; Tissue protection and repair research
- Chemical data
- CAS 1208243-50-8 · C52H91N17O21 · 1257.35 Da
- Amino acids
- 11 aa
Chonluten
aka EDL, Glu-Asp-Leu
How it works: An oral short peptide, similar to Bronchogen, that switches on lung-repair genes, studied for airway anti-aging.
Lung tissue anti-aging; bronchial function; oral capsule form
Research dose
1-2 capsule, Daily or as directed
Real-world (reported)
1–2 capsules daily ×30–60 days. 2× per year.
Administration
Oral
Timing
Any time with food
Cycle length
30–60 days oral
Real-world figures are community-reported, not medical advice.
Common side effects: Generally well tolerated; mild GI effects
Community take: [ANECDOTAL] Oral lung bioregulator. Convenient vs injectable Bronchogen. Russian commercial product.
- Onset
- Respiratory improvements 4–8 wks
- Half-life
- Hours (oral)
- Storage
- Dry: Room temperature; dry
- Reconstitution
- N/A (pre-formulated)
- Rare side effects
- Limited long-term Western data
- Contraindications
- Active lung disease (consult physician); pregnancy
- Drug interactions
- No significant interactions
- Recommended bloodwork
- Respiratory function assessments; inflammatory markers
- Stacks well with
- Bronchogen: injectable complement.
- Secondary uses
- Respiratory aging protection; anti-inflammatory bronchial support
- Research status
- Russian Khavinson lab; available commercially as Chonluten capsules in Russia/Eastern Europe
- FDA status
- No
- Legal status
- US: Research use only · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $20–$50 / pack
PNC-27
aka p53-derived Peptide, HDM2-binding Peptide, PNC27 Anticancer Peptide
How it works: An experimental cancer-research peptide that punches holes in cancer cells showing a specific surface marker while sparing normal cells.
Cancer cell-selective apoptosis induction (research only)
Real-world (reported)
Pure research; no community adoption
Administration
Research only
Timing
Research only
Cycle length
Research only
Real-world figures are community-reported, not medical advice.
Common side effects: No human safety data; theoretical cytokine release
Community take: [ANECDOTAL] NO ESTABLISHED HUMAN PROTOCOL
- Onset
- Research only
- Half-life
- Research only
- Reconstitution
- Freeze –20°C; protect from light
- Rare side effects
- ALL — no human use; active malignancy is paradox (target vs no data)
- Contraindications
- None established; Not approved for human use; any administration outside of authorized research co; Active autoimmune disease (theoretical concern due to potential immune stimulati; Known hypersensitivity to any component of the peptide formulation; Pregnancy and lactation (no reproductive toxicity data available)
- Drug interactions
- Research biomarkers only
- Recommended bloodwork
- None established for humans
- Stacks well with
- [ANECDOTAL] Extreme research niche only. No significant gray-market community.
- Secondary uses
- Potential senescent cell clearance; oncology adjunct (research)
- Research status
- Preclinical cell culture studies; very limited animal data; no human clinical trials
- FDA status
- No
- Legal status
- US: Legal for research · UK: Legal research chemical · Canada: Schedule 4 · Australia: Unregulated · EU: Extremely limited; research labs
- Typical price
- Not applicable
- Research evidence
- low
- Indications
- Selective anticancer peptide research; HDM-2 membrane expression and targeting studies; Cancer cell membrane permeabilization research; p53-HDM-2 interaction studies
- Chemical data
- CAS 1159861-00-3 · C188H293N53O44S · 4031.7 Da
- Amino acids
- 32 aa
Livagen
aka KEDP, Lys-Glu-Asp-Pro, Prostoma
How it works: A short peptide that switches on immune- and liver-cell repair genes, studied for immune support and anti-aging.
Immune reconstitution; liver anti-aging; detoxification support
Research dose
5-10 mg, Daily ×10 day course
Real-world (reported)
5–10 mg SC ×10 days; 2 cycles/year.
Administration
SC
Timing
Any time
Cycle length
10 days; 2× per year
Real-world figures are community-reported, not medical advice.
Common side effects: Generally well tolerated
Community take: [ANECDOTAL] Russian longevity protocol immune/liver component. Small Western community.
- Onset
- Immune/liver biomarker changes
- Half-life
- Hours
- Storage
- Dry: Fridge 2–8°C; freeze · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 1 mL BAC water to 10 mg vial
- Rare side effects
- Very limited Western data
- Contraindications
- Active liver disease (consult hepatologist); pregnancy; Active prostate cancer or strong family history of prostate cancer (theoretical; Pregnancy and breastfeeding (no safety data); Children and adolescents (no indication; no safety data); Known hypersensitivity to short peptides
- Drug interactions
- Hepatotoxic drugs (inform physician)
- Recommended bloodwork
- LFTs; CBC; immune markers
- Stacks well with
- Thymalin: immune complement. Epitalon: longevity protocol.
- Secondary uses
- Hepatoprotection; post-viral immune recovery
- Research status
- Russian Khavinson lab liver and immune aging studies
- FDA status
- No
- Legal status
- US: Research use only · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $30–$70 / 10 mg vial
- Research evidence
- very-low
- Indications
- Preclinical research into prostate aging and BPH-like pathology; Bioregulatory peptide gene-expression studies; Comparative research alongside other Khavinson short peptides (Epitalon, Vilon, Thymalin)
- Chemical data
- C20H36N6O8 · 488.54 Da
- Amino acids
- 15 aa
VIP
aka Vasoactive Intestinal Peptide, Vasoactive Intestinal Peptide, VIP Peptide, PHM-27
How it works: A natural signaling peptide that widens blood vessels, opens airways, calms inflammation, and supports gut and circadian function.
POTS/dysautonomia (emerging); mast cell activation; pulmonary arterial hypertension (VPAC agonism); immune modulation
Research dose
50-200 pmol/kg/min (IV); or 50–200 mcg SubQ, Variable by indication
Real-world (reported)
100 mcg SubQ 1×/day — extremely limited community protocol. Most use via clinic/IV administration.
Administration
SubQ / IV (clinical)
Timing
Any time
Cycle length
Per protocol
Real-world figures are community-reported, not medical advice.
Common side effects: Facial flushing; hypotension; nausea (dose-dependent); GI effects
Community take: [ANECDOTAL] Very limited community experience due to instability and dosing complexity. Used by some POTS/dysautonomia community with reported benefit.
- Onset
- Variable by indication
- Half-life
- Very short (~1 min IV; longer SubQ)
- Storage
- Dry: Freeze –20°C; very labile; protect from all light and heat · Reconstituted: Refrigerate; use IMMEDIATELY after reconstitution; discard remaining
- Reconstitution
- Add 1 mL BAC water to 0.2 mg vial; very low doses used
- Rare side effects
- Significant hypotension; bronchospasm (rare); rapid degradation → use within minutes
- Contraindications
- Hypotension; cardiovascular disease; pregnancy; Severe hypotension or hemodynamic instability; Decompensated heart failure (risk of further vasodilation and fluid shifts); Pregnancy (insufficient safety data; VIP has roles in reproductive biology that; Antihypertensive medications (ACE inhibitors; ARBs; calcium channel blockers; be
- Drug interactions
- Antihypertensives (additive hypotension)
- Recommended bloodwork
- BP and HR monitoring; cardiac evaluation baseline
- Stacks well with
- BPC-157: GI healing complement. SS-31: mitochondrial/cardiac synergy.
- Secondary uses
- GI motility; neuroprotection; anti-inflammatory; sleep regulation
- Research status
- Multiple Phase 2 human trials (PAH — Aviptadil; POTS; COVID-19 respiratory); Aviptadil (FDA Breakthrough Therapy for COVID-19 ARDS 2020)
- FDA status
- No
- Legal status
- US: Research use only; Aviptadil had FDA Breakthrough Therapy (COVID-19 ARDS) · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $100–$500 / 0.2 mg (limited supply)
- Research evidence
- low
- Indications
- Pulmonary hypertension research; Neuroprotection studies; Inflammatory bowel disease research; Circadian biology research
- Chemical data
- CAS 37221-79-7 · C147H237N43O43S1 · 3326.8 Da
- Amino acids
- 111 aa
Bronchogen
aka AEDL, Ala-Glu-Asp-Leu
How it works: A short peptide that switches on lung-tissue repair genes, studied for protecting and anti-aging the airways.
Lung tissue anti-aging; bronchial protection; COPD support
Research dose
5-10 mg, Daily ×10 day course
Real-world (reported)
5–10 mg SC ×10 days; 1–2 cycles/year.
Administration
SC
Timing
Any time
Cycle length
10 days; 1–2× per year
Real-world figures are community-reported, not medical advice.
Common side effects: Generally well tolerated
Community take: [ANECDOTAL] Russian COPD and smoker recovery protocols. Small Western community.
- Onset
- Respiratory biomarker changes
- Half-life
- Hours
- Storage
- Dry: Fridge 2–8°C; freeze · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 1 mL BAC water to 10 mg vial
- Rare side effects
- Very limited Western data
- Contraindications
- Active lung disease (consult physician); pregnancy
- Drug interactions
- Corticosteroids; bronchodilators (inform physician)
- Recommended bloodwork
- PFTs; inflammatory markers
- Stacks well with
- Chonluten: oral complementary. Full Khavinson respiratory protocol.
- Secondary uses
- Anti-inflammatory bronchial; lung fibrosis prevention (preclinical)
- Research status
- Russian Khavinson lab; COPD and aging lung animal studies
- FDA status
- No
- Legal status
- US: Research use only · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $30–$70 / 10 mg vial
Thymulin
aka FTS, Facteur Thymique Serique
How it works: A zinc-bound thymic peptide that helps mature immune T-cells and calm inflammation, studied for immune support.
T-cell maturation; immune reconstitution; anti-inflammatory aging support
Research dose
5-20 mg, Daily or every other day
Real-world (reported)
5–10 mg SubQ daily ×4 weeks. Ensure zinc adequacy.
Administration
SubQ
Timing
Any time
Cycle length
4–8 weeks
Real-world figures are community-reported, not medical advice.
Common side effects: Generally well tolerated; rare flu-like activation
Community take: [ANECDOTAL] Endogenous hormone replacement concept. Reports of improved immunity in older users.
- Onset
- Immune improvements 4–8 wks
- Half-life
- Hours
- Storage
- Dry: Fridge 2–8°C; light sensitive; zinc stability · Reconstituted: Refrigerate; use within 21 days
- Reconstitution
- Add 1 mL BAC water; confirm zinc in formulation
- Rare side effects
- Zinc-related if formulation inconsistent; limited Western data
- Contraindications
- Autoimmune on immunosuppressants; pregnancy
- Drug interactions
- Immunosuppressants; zinc interactions
- Recommended bloodwork
- CBC; zinc levels; CD4/CD8
- Stacks well with
- Thymosin Alpha-1: complementary immune support. Thymalin: Khavinson thymic complement.
- Secondary uses
- Hair growth (emerging); depression (serotonin interaction); pain modulation
- Research status
- Multiple preclinical studies; some human age-related data
- FDA status
- No
- Legal status
- US: Research use only · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $40–$100 / 10 mg vial
Vilon
aka KE, Lys-Glu, KE dipeptide
How it works: The simplest Khavinson peptide - an oral dipeptide that activates immune- and thymus-cell anti-aging genes.
Immune anti-aging; thymic function support; longevity
Research dose
1-2 mg, Daily
Real-world (reported)
1–2 mg SC or oral daily ×10–30 days; 2–4 cycles/year.
Administration
SC / Oral
Timing
Any time
Cycle length
10–30 days; 2–4× per year
Real-world figures are community-reported, not medical advice.
Common side effects: Generally well tolerated
Community take: [ANECDOTAL] Russian longevity protocol. Oral convenience is advantage. Small Western community.
- Onset
- Immune/biomarker changes over weeks
- Half-life
- Hours
- Storage
- Dry: Fridge 2–8°C; freeze · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 1 mL BAC water to 2 mg vial
- Rare side effects
- Very limited Western data
- Contraindications
- Autoimmune on immunosuppressants; pregnancy; No formal contraindications have been established because no human clinical tria; Pregnant or breastfeeding women should avoid vilon as no reproductive toxicology; Individuals on immunosuppressive therapy should avoid vilon due to the theoretic
- Drug interactions
- Immunosuppressants
- Recommended bloodwork
- CBC; immune markers (optional)
- Stacks well with
- Thymalin: complement. Epitalon: longevity protocol.
- Secondary uses
- Anti-tumor (Russian data); oxidative stress reduction; lifespan extension (animal)
- Research status
- Russian Khavinson lab; lifespan extension animal studies
- FDA status
- No
- Legal status
- US: Research use only · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $20–$50 / 2 mg vial
- Research evidence
- low
- Indications
- Geroprotective research (lifespan extension in animal models); Immunomodulation and thymic function support (preclinical); Epigenetic aging research (chromatin remodeling); Peptide bioregulator research
- Chemical data
- C11H21N3O5 · 275.3 Da
- Amino acids
- 16 aa
Substance P
aka Neuropeptide, SP, Tachykinin
How it works: Substance P is released by neurons when experiencing painful stimuli and helps transmit pain messages to the brain and spinal cord.
Pain transmission and modulation, nausea and vomiting prevention, depression/mood disorders, inflammation
Research dose
10-250 nmol/kg
Administration
Intravenous injection; intracerebral infusion
Common side effects: Mood worsening, increased REM latency, increased time awake, increased cortisol and thyroid stimulating hormone
- Half-life
- Not explicitly stated in sources
- Rare side effects
- Stevens–Johnson syndrome, neutropenia, angioedema, QT prolongation (with NK antagonists)
- Secondary uses
- Colitis, dental pain, anxiety disorders, stress response
- Research status
- Phase II Clinical Trials; Active Research
- FDA status
- Not directly approved as therapeutic peptide; NK1 antagonists (aprepitant) approved for chemotherapy-induced nausea/vomiting
Afamelanotide
aka Scenesse, Melanotan I, Melanotan-1
How it works: Afamelanotide (Scenesse) is a synthetic tridecapeptide analog of alpha-MSH that activates the melanocortin 1 receptor (MC1R) to stimulate eumelanin production. FDA-approved in 2019 for increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP), it is administered as a subcutaneous implant every 2 months.New to skin peptides?Browse all skin peptides →Table of Contents📌T
Erythropoietic protoporphyria (EPP) photoprotection (FDA/EMA approved); Vitiligo repigmentation (Phase 3 investigational)
Administration
SC
Timing
Administered by certified healthcare provider as a bioresorbable implant above the anterior supra-iliac crest. Typically 5-6 implants per year.
Cycle length
Seasonal (spring through fall)
- Half-life
- Approximately 15 hours (from subcutaneous implant with sustained release over 60
- Reconstitution
- Sterile water
- Contraindications
- Known hypersensitivity to afamelanotide or any component of the implant; Patients should not have unexamined suspicious melanocytic lesions prior to impl; No clinically significant drug interactions have been identified. Afamelanotide; Afamelanotide does not replace the need for sun protection measures. Patients sh
- Research status
- Approved
- FDA status
- FDA approved
- Legal status
- US: Approved
- Research evidence
- high
- Indications
- Erythropoietic protoporphyria (EPP) photoprotection (FDA/EMA approved); Vitiligo repigmentation (Phase 3 investigational)
- Chemical data
- CAS 75921-69-6 · C78H111N21O19 · 1647 Da
- Amino acids
- 260 aa
Alpha-Melanocyte-Stimulating Hormone
aka ACTH 1-13 fragment, α-MSH, MSH, Melanocyte-Stimulating Hormone
How it works: Alpha-MSH is a 13-amino-acid endogenous neuropeptide derived from proopiomelanocortin (POMC), acting as a non-selective agonist at melanocortin receptors, playing central roles in pigmentation, appetite regulation, anti-inflammatory signaling, neuroprotection, and immune modulation.
Appetite suppression, anti-inflammatory signaling, immune modulation, neuroprotection
Research dose
1-100 mcg, [ANECDOTAL]—research studies used varied frequencies; intranasal single dose studies; oral ingestion in animal models; intraperitoneal injection in mouse models
Administration
Subcutaneous injection, intranasal, oral ingestion (research models), topical (eye drops), intravenous
Common side effects: Skin hyperpigmentation, darkening of preexisting nevi and ephelides, and development of melanocytic nevi are known potential side effects
- Rare side effects
- At doses ≥1 mg (central administration in animal models): increased salivation, agitation, ataxia, respiratory distress, and death (in 30% of animals)
- Secondary uses
- Fever reduction, ischemia/reperfusion injury protection, rheumatoid arthritis, inflammatory bowel disease, contact dermatitis, dry eye disease
- Research status
- Preclinical and animal model research; synthetic analogs in clinical trials
- Legal status
- US: Despite a ban by the United States Food and Drug Administration, commercially produced, unregulated peptide analogs of α-MSH (eg, melanotan, melanotan II) remain available for sale online
Cortistatin
aka CST-14, Cortistatin-14, CST-17
How it works: Cortistatin is a 14-amino-acid cyclic neuropeptide (CST-14) discovered in 1996 in the cerebral cortex. It shares 11 of 14 residues with somatostatin-14 but is encoded by a separate gene (CORT) and has distinct physiological functions. Cortistatin selectively promotes deep slow-wave sleep, exerts potent anti-inflammatory effects in models of IBD, sepsis, and arthritis, and regulates cortical excita
Sleep regulation research (slow-wave sleep promotion); Anti-inflammatory and immunomodulatory research; Neuroprotection and cortical excitability studies; Anticonvulsant research
Administration
IV
Timing
Preclinical routes only (ICV and IP in animal models). No clinically applicable route has been established for human use.
Cycle length
Acute single-dose to 10 days
- Half-life
- Short (minutes); exact value not well characterized in humans
- Contraindications
- No formal contraindications established as cortistatin has not entered human cli; Theoretical concern in patients with growth hormone deficiency due to potential; Theoretical concern in patients with diabetes due to potential effects on insuli; Somatostatin analogs (octreotide, lanreotide): Potential additive effects on s
- Research status
- Preclinical
- FDA status
- Not approved
- Legal status
- US: Preclinical Research
- Research evidence
- low
- Indications
- Sleep regulation research (slow-wave sleep promotion); Anti-inflammatory and immunomodulatory research; Neuroprotection and cortical excitability studies; Anticonvulsant research
- Chemical data
- CAS 193829-96-8 · C81H113N19O19S2 · 1721.01 Da
- Amino acids
- 69 aa
Glutathione
aka GSH, L-Glutathione, Gamma-L-Glutamyl-L-Cysteinyl-Glycine
How it works: Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. It is the most abundant intracellular antioxidant in mammalian cells and plays critical roles in detoxification, immune modulation, and protection against oxidative stress.New to immune peptides?Browse all immune peptides →Table of Contents📌TL;DR•Functions as the primary intracellular antioxidant•Supports hepatic detoxifica
Antioxidant supplementation research; Hepatoprotection and detoxification studies; Immune function modulation; Skin lightening and dermatological research
Administration
IV
Timing
No specific timing requirement; IV sessions typically in clinical setting✓ Rotate injection sites
Cycle length
4-12 weeks for injectable protocols; ongoing for oral supplementation
- Half-life
- ~10.9 minutes (IV in plasma); ~1.6 minutes (oral plasma signal); intracellular t
- Contraindications
- Sulfite-sensitive asthma (inhaled/nebulized glutathione contraindicated due to b; Active cancer receiving platinum-based chemotherapy (GSH may reduce chemotherapy; Known hypersensitivity to glutathione formulations or excipientsFrequency distri; Platinum chemotherapies (cisplatin, carboplatin): elevated GSH and GST reduce pl
- Research status
- Preclinical
- FDA status
- Not approved
- Legal status
- US: Preclinical Research
- Research evidence
- moderate
- Indications
- Antioxidant supplementation research; Hepatoprotection and detoxification studies; Immune function modulation; Skin lightening and dermatological research
- Chemical data
- CAS 70-18-8 · C10H17N3O6S · 307.32 Da
- Amino acids
- 139 aa
Icotrokinra
aka JNJ-2113, JNJ-77242113, PN-235
How it works: Icotrokinra (JNJ-2113) is a first-in-class targeted oral peptide that selectively antagonizes the interleukin-23 receptor. In the phase 3 ICONIC-LEAD trial, once-daily oral dosing achieved 65% IGA 0/1 response at week 16 vs 8% placebo (P<0.001). Johnson & Johnson submitted an NDA to the FDA in July 2025.New to skin peptides?Browse all skin peptides →Table of Contents📌TL;DR•First oral peptide ther
Moderate-to-severe plaque psoriasis (adults and adolescents 12+); Scalp and genital psoriasis (high-impact sites); Ulcerative colitis (Phase 2b, under investigation)
Administration
Oral
Timing
Once-daily oral tablet; no specific timing relative to meals reported
Cycle length
OngoingStep-wise Titration
- Half-life
- Supports once-daily oral dosing based on pharmacokinetic modeling
- Storage
- Dry: Store at room temperature; protect from moisture and light
- Contraindications
- Known hypersensitivity to icotrokinra or any excipient; Active serious infections (consistent with immunomodulatory therapy guidelines)F; No clinically significant drug interactions have been identified in clinical tri; Live vaccines should be avoided during treatment, consistent with recomm
- Research status
- Phase 3
- FDA status
- Not approved
- Legal status
- US: Investigational
- Research evidence
- high
- Indications
- Moderate-to-severe plaque psoriasis (adults and adolescents 12+); Scalp and genital psoriasis (high-impact sites); Ulcerative colitis (Phase 2b, under investigation)
- Chemical data
- CAS 2763602-16-8 · C90H120N20O22S2 · 1898.19 Da
- Amino acids
- 160 aa
io102-io103
How it works:
Motixafortide
aka BL-8040, BKT140, APHEXDA
How it works: Motixafortide (APHEXDA, BL-8040) is an FDA-approved cyclic peptide CXCR4 antagonist used in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells for collection and autologous transplantation in patients with multiple myeloma. It has high affinity for CXCR4 (Ki 0.32 nM) and extended activity exceeding 48 hours. The Phase 3 GENESIS trial showed 92.5% of patients achieved adequate
Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma (FDA-approved); Stem cell mobilization for gene therapy in sickle cell disease (investigational); Pancreatic cancer (investigational, Orphan Drug Designation)
Administration
SC
Timing
Administer 10-14 hours prior to each planned apheresis session; given in conjunction with G-CSF priming (4-5 days prior)
Cycle length
1-3 doses over mobilization period
- Half-life
- Extended clinical activity exceeding 48 hours
- Contraindications
- Known hypersensitivity to motixafortide or any excipient; Patients unable to receive required premedicationFrequency distribution of repor; Motixafortide is used in combination with filgrastim (G-CSF), which is an integr; No other drug interactions have been formally characterized per prescribing info
- Research status
- Phase 3
- FDA status
- Not approved
- Legal status
- US: Approved
- Research evidence
- high
- Indications
- Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma (FDA-approved); Stem cell mobilization for gene therapy in sickle cell disease (investigational); Pancreatic cancer (investigational, Orphan Drug Designation)
- Chemical data
- CAS 664334-36-5 · C97H144FN33O19S2 · 2159.55 Da
- Amino acids
- 197 aa
Pegcetacoplan
aka Empaveli, Syfovre, APL-2
How it works: Pegcetacoplan is a PEGylated cyclic peptide C3 complement inhibitor approved for two distinct indications: paroxysmal nocturnal hemoglobinuria (PNH) as Empaveli (FDA May 2021, subcutaneous) and geographic atrophy secondary to age-related macular degeneration as Syfovre (FDA February 2023, intravitreal). Developed by Apellis Pharmaceuticals, it targets C3 at the convergence of all three complement
Paroxysmal nocturnal hemoglobinuria (Empaveli, subcutaneous); Geographic atrophy secondary to AMD (Syfovre, intravitreal injection)
Administration
subcutaneous (PNH) or intravitreal (GA)
Timing
PNH: Self-administered via infusion pump over 20-30 minutes. GA: Administered by retinal specialist in clinic.✓ Rotate injection sites
Cycle length
OngoingStep-wise Titration
- Half-life
- ~8 days (SC), supporting twice-weekly dosing for PNH
- Storage
- Dry: Refrigerate at 2-8 degrees C. Protect from light. Do not freeze.
- Contraindications
- Patients with unresolved serious infection caused by encapsulated bacteria; Patients not vaccinated against Neisseria meningitidis, Streptococcus pneumoniae; Known hypersensitivity to pegcetacoplan or any excipient; Active ocular or periocular infection (Syfovre)Frequency distribution of reporte
- Research status
- Approved
- FDA status
- FDA approved
- Legal status
- US: Approved
- Research evidence
- high
- Indications
- Paroxysmal nocturnal hemoglobinuria (Empaveli, subcutaneous); Geographic atrophy secondary to AMD (Syfovre, intravitreal injection)
- Chemical data
- CAS 2019171-69-6 · C1970H3848N50O947S4 · 43500 Da
- Amino acids
- 113 aa
Tat-Beclin-1
aka Tat-BECN1, TB-peptide, Tat-Beclin 1 peptide
How it works: Tat-Beclin-1 (Tat-BECN1) is a cell-permeable autophagy-inducing peptide designed by fusing 11 amino acids from the HIV-1 Tat protein transduction domain with 18 amino acids from beclin 1 (residues 267-284) via a diglycine linker. Developed by Shoji-Kawata, Levine, and colleagues at UT Southwestern, it potently induces autophagy by releasing beclin 1 from its negative regulator GAPR-1/GLIPR2 at the
Autophagy research tool compound; Antiviral research (West Nile, chikungunya, HIV-1); Cancer autophagy research (HER2-positive breast cancer); Neurodegenerative disease research (protein aggregate clearance); Cell death mechanism research (autosis)
Administration
IV
Timing
In vitro concentrations range from 0.5-50 micromolar. In vivo mouse studies used daily IP injection. No human dosing data exists.
Cycle length
Hours to 20 days (varies by model)
- Half-life
- Not formally characterized in vivo. The L-form is expected to be rapidly degrade
- Contraindications
- No formal contraindications established due to absence of human clinical trials.; Active malignancies where autophagy may promote tumor survival (established tumo; Patients on cardiac glycosides (digoxin), as these drugs inhibit autosis via Na+; Pregnant or breastfeeding w
- Research status
- Preclinical
- FDA status
- Not approved
- Legal status
- US: Preclinical Research
- Research evidence
- low
- Indications
- Autophagy research tool compound; Antiviral research (West Nile, chikungunya, HIV-1); Cancer autophagy research (HER2-positive breast cancer); Neurodegenerative disease research (protein aggregate clearance); Cell death mechanism research (autosis)
- Chemical data
- CAS 1423821-88-8 · C164H251N57O45 · 3028.44 Da
- Amino acids
- 42 aa
Rusfertide
aka PTG-300
How it works: Rusfertide (PTG-300) is a synthetic hepcidin mimetic peptide that controls erythrocytosis in polycythemia vera by degrading ferroportin and restricting iron availability for red blood cell production. Administered subcutaneously once weekly, it has demonstrated 77% clinical response rates in the phase 3 VERIFY trial and received FDA Breakthrough Therapy Designation.New to immune peptides?Browse al
Polycythemia vera (erythrocytosis control); Hereditary hemochromatosis (investigational)
Administration
SC
Timing
Consistent day of week; dose titrated to maintain hematocrit <45%✓ Rotate injection sites
Cycle length
OngoingStep-wise Titration (12 weeks)
- Half-life
- : ~
- Storage
- Dry: Refrigerate at 2-8 degrees C. Protect from light.
- Contraindications
- Severe pre-existing iron deficiency anemia (rusfertide further restricts iron av; Known hypersensitivity to rusfertide or any excipientFrequency distribution of r; No clinically significant drug interactions have been identified in clinical tri
- Research status
- Phase 3
- FDA status
- Not approved
- Legal status
- US: Investigational
- Research evidence
- moderate
- Indications
- Polycythemia vera (erythrocytosis control); Hereditary hemochromatosis (investigational)
- Chemical data
- CAS 1628323-80-7 · C114H181N27O28S2 · 2441.98 Da
- Amino acids
- 75 aa
zilucoplan
How it works:
Example stacks
Immune Support - Beginner
Thymosin Alpha-1 is the most clinically validated immune peptide - used as a pharmaceutical in 35+ countries.
- • Space injections evenly - e.g. Monday and Thursday
- • Run the full 4-6 week cycle
- • Combine with adequate sleep, vitamin D, and zinc
Immune Support - Intermediate
TA-1 modulates adaptive immunity while BPC-157 reduces systemic inflammation that suppresses immune function.
- • Take BPC-157 orally if gut inflammation is a contributing factor
- • Run the full 6-week cycle even after symptoms improve
- • Track recovery speed from minor illnesses
Community outcome data
Collected from users researching this goal. Not a clinical database - for general reference only.
Share your experience
Your experience helps others research this goal. All submissions are anonymous.
Ready to actually use this research?
FREETwo tools that turn this research into something you can actually use - no signup needed.
For educational and research purposes only. Not medical advice. Always consult a qualified healthcare provider before using any research compound.